First-In-Human Study of AK1320 Encapsulated Microspheres (AK1320 MS) In Subjects With Degenerative Spondylolisthesis and Concomitant Symptomatic Spinal Stenosis Who Are Undergoing Decompression And Single Level Instrumented Posterolateral Lumbar Autograft
Unknown Phase 1 NCT04483297
Study Description
The safety and efficacy of AK1320 MS will be evaluated in patients with degenerative spondylolisthesis and concomitant symptomatic spinal stenosis who are undergoing decompression and single level instrumented posterolateral lumber autograft fusion surgery.
Study Details
- Registry ID:
- NCT04483297
- Conditions:
- Degenerative Spondylolisthesis, Spinal Stenosis
- Phase:
- Phase 1
- Target Enrollment:
- 30 participants
- Start Date:
- Age Range:
- 22–80 years
- Healthy Volunteers:
- No
Study Locations (7 sites)
-
Queen Elizabeth II Health Sciences Centre
Halifax, Nova Scotia, Canada -
Centre Hospitalier Universitaire de Québec Laval
Québec, Quebec, Canada -
Montreal General Hospital
Montreal, Quebec, Canada -
Hôpital Sacré-Coeur de Montréal
Montreal, Quebec, Canada -
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada -
London Health Sciences Centre
London, Ontario, Canada -
Royal Alexandra Hospital
Edmonton, Alberta, Canada
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.